Cookies

Like most websites The Analytical Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Techniques & Tools Pharma & Biopharma, Technology

Nanofluidic PAT

Applying quality control to living organisms is tricky at best – but also crucial: the quality of biopharmaceuticals has a clear impact on both safety and efficacy. And so quality assurance is typically conducted at the end of the (lengthy and costly) biomanufacturing process – but is that logical? “If the manufacturing system produces low-quality or abnormal biologics, it is hard to see whether the product quality and system operation are normal or not during the manufacturing process through conventional analytics systems,” says Sunghee Ko, Postdoctoral Associate of Jongyoon Han’s laboratory at the Massachusetts Institute of Technology. “Because of this, current quality measurements (for example, release analytics) can lead to money loss and a disruption of biologic supplies when manufacturing has problems.”

Read the full article now

Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Analytical Scientist magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

William Aryitey

Register to The Analytical Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Analytical Scientist magazine

Register